By Gina Shaw
Demand has been increasing for glucagon-like peptide-1 (GLP-1) agonist drugs such as semaglutide (Wegovy, Novo Nordisk) and tirzepatide (Zepbound, Eli Lilly), but these medications are often excluded from coverage in employer health plans, and coverage is expected to decline even more during 2025, said experts from the healthcare practice law firm Frier Levitt in a May 15 webinar. What’s more, pharmacies—particularly community-based ones—face losses on these drugs
MAY 27, 2025